Onderzoek naar het voorkómen van nierfalen na levertransplantatie door aanpassing van de afweerremmende middelen.
- Conditions
- English: Advagraf, liver transplantation, optimizing immunosuppressive therapyDutch:Advagraf, levertransplantatie, optimaliseren immunosuppressieve therapie, effectiviteit en veiligheid
- Registration Number
- NL-OMON26731
- Lead Sponsor
- Foundation for Liver and Gastrointestinal Research (SLO)Department of Gastroenterology & HepatologyErasmus Medical Center Rotterdam‘s Gravendijkwal 230, Room HA 2043015 CE Rotterdam, The NetherlandsTel: +31 10 703 5942 Fax: +31 10 436 5916
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 196
Inclusion Criteria
1. Primary liver transplantation or retransplantation within 14 days after first transplantation;
2. Use of Advagraf at least 2 weeks prior to randomization;
Exclusion Criteria
1. Treatment with investigational drugs within 3 months before start of therapy;
2. Multi organ transplantation;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with cGFR < 60ml/min at 36 months after transplantation.
- Secondary Outcome Measures
Name Time Method